Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Authors :: Roeland E Wasmann
Cornelis Smit
Roger J. M. Brüggemann
René M J Wiezer
Jill Adler-Moore
David M. Burger
Eric P H van Dongen
Yvo de Beer
Catherijne A. J. Knibbe
RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome
MUMC+: DA KFT Laboratorium (9)
Source :: Clinical Infectious Diseases, 70, 2213-2215, Clinical Infectious Diseases, 70(10):ciz885, 2213-2215. Oxford University Press, Clinical Infectious Diseases, 70(10), 2213-2215. Oxford University Press, Clinical Infectious Diseases, 70, 10, pp. 2213-2215
Publication Year :: 2020
Abstract: Contains fulltext : 220654.pdf (Publisher’s version ) (Open Access) In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.